{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:36:52Z","timestamp":1783042612111,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009239","name":"Horowitz Foundation for Social Policy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drugalcdep.2025.112775","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T19:38:31Z","timestamp":1751571511000},"page":"112775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy"],"prefix":"10.1016","volume":"274","author":[{"given":"Benjamin A.","family":"Barsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shapei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith B.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.112775_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104058","article-title":"Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: a qualitative systematic review","volume":"117","author":"Adams","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib2","unstructured":"Alderks, C.E., 2017. Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update), The CBHSQ Report. SAMHSA."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib3","first-page":"361","article-title":"Internet drug prohibition and the opioid overdose crisis","volume":"99","author":"Barsky","year":"2024","journal-title":"Wash. L. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.4455","article-title":"Rates of opioid overdose among racial and ethnic minority individuals released from prison","volume":"4","author":"Barsky","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib5","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison - a high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2732","article-title":"Prison buprenorphine implementation and postrelease opioid use disorder outcomes","volume":"7","author":"Bovell-Ammon","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib8","unstructured":"Bureau of Substance Addiction Services, 2020. COVID-19 Alert for Opioid Treatment Programs [WWW Document]. URL \u3008https:\/\/careersofsubstance.org\/sites\/careersofsubstance\/files\/COVID-19-OTP-BSAS%2520guidance%2520%25283.18.2020%2529.pdf\u3009 (accessed 8.19.24)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib9","unstructured":"Bustillos, E., 2023. New report shows highest opioid-related death rate to date for Mass. in 2022 [WWW Document]. GBH. URL \u3008https:\/\/www.wgbh.org\/news\/health\/2023-06-22\/new-report-shows-highest-opioid-related-death-rate-to-date-for-mass-in-2022\u3009 (accessed 8.19.24)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40352-023-00209-w","article-title":"Medications for opioid use disorder during incarceration and post-release outcomes","volume":"11","author":"Cates","year":"2023","journal-title":"Health Justice"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib11","unstructured":"CDC, 2022. Drug Overdose Mortality by State [WWW Document]. URL \u3008https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm\u3009 (accessed 8.19.24)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/08897077.2021.2010251","article-title":"I wanted something that was more flexible: a qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program","volume":"43","author":"Checkley","year":"2022","journal-title":"Subst. Abus."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6147","article-title":"Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic","volume":"4","author":"Currie","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108216","article-title":"COVID-19 and treating incarcerated populations for opioid use disorder","volume":"124","author":"Donelan","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108197","article-title":"Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic","volume":"121","author":"Dunn","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108276","article-title":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","volume":"123","author":"Figgatt","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"It\u2019s like \u2018liquid handcuffs: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib18","article-title":"COVID-19 impact on opioid overdose after jail release in Massachusetts","volume":"6","author":"Friedmann","year":"2023","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/10826084.2022.2155480","article-title":"And then COVID Hits: a qualitative study of how jails adapted services to treat opioid use disorder during COVID-19","volume":"58","author":"Harrington","year":"2023","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib21","article-title":"Fatal and nonfatal opioid overdose risk following release from prison: a retrospective cohort study using linked administrative data","volume":"147","author":"Hartung","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib22","first-page":"44","article-title":"Homelessness and housing insecurity among former prisoners","volume":"1","author":"Herbert","year":"2015","journal-title":"Russell Sage Found. J. Soc. Sci."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108801","article-title":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: a mixed methods analysis","volume":"141","author":"Hoffman","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108927","article-title":"Racial inequity in medication treatment for opioid use disorder: exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib25","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1001\/jama.2020.21512","article-title":"Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic","volume":"324","author":"Huskamp","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib26","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2024.19914","article-title":"Methadone\u2019s moment","volume":"332","author":"Incze","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamapsychiatry.2023.4958","article-title":"Systemic racism as a determinant of health inequities for people with substance use disorder","volume":"81","author":"Jegede","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-019-0145-5","article-title":"A conceptual model for understanding post-release opioid-related overdose risk","volume":"14","author":"Joudrey","year":"2019","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib31","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsat.2009.03.002","article-title":"A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease","volume":"37","author":"Kinlock","year":"2009","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib33","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","article-title":"Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis","volume":"16","author":"Levander","year":"2021","journal-title":"Addict. Sci. Clin. Pr."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder","volume":"179","author":"Lin","year":"2022","journal-title":"AJP"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States","volume":"46","author":"Lister","year":"2020","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib39","series-title":"Medications for opioid use disorder save lives","author":"Mancher","year":"2019"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-soc-073014-112326","article-title":"Incarceration and health","volume":"41","author":"Massoglia","year":"2015","journal-title":"Annu. Rev. Sociol."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib42","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.acap.2013.08.002","article-title":"Use of interrupted time series analysis in evaluating health care quality improvements","volume":"13","author":"Penfold","year":"2013","journal-title":"Acad. Pediatr."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","article-title":"Opioid overdose mortality among former North Carolina Inmates: 2000\u20132015","volume":"108","author":"Ranapurwala","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib44","unstructured":"SAMHSA, 2024. Methadone Take-Home Flexibilities Extension Guidance [WWW Document]. URL \u3008https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance\u3009(accessed 77.25)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib45","unstructured":"SAMHSA, n.d. Opioid Treatment Program Directory [WWW Document]. URL \u3008https:\/\/dpt2.samhsa.gov\/treatment\/\u3009 (accessed 4.4.25)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib46","unstructured":"Serres, C., 2024. \u2018Game changer\u2019: Mass. doctors hail new federal rule expanding access to methadone. Boston Globe."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib47","article-title":"Treatment setting among individuals with opioid use and criminal legal involvement, housing instability, or Medicaid insurance, 2015-2021","volume":"8","author":"Shearer","year":"2023","journal-title":"Drug Alcohol Depend. Rep."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib48","unstructured":"State Office of Rural Health, n.d. State Office of Rural Health Rural Definition [WWW Document]. URL \u3008https:\/\/www.mass.gov\/info-details\/state-office-of-rural-health-rural-definition\u3009 (accessed 8.19.24)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11606-022-07891-w","article-title":"Buprenorphine treatment episodes during the first year of COVID: a retrospective examination of treatment initiation and retention","volume":"38","author":"Stein","year":"2023","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib50","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.2105\/AJPH.2021.306654","article-title":"Structural adaptations to methadone maintenance treatment and take-home dosing for opioid use disorder in the era of COVID-19","volume":"112","author":"Suen","year":"2022","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112775_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110985","article-title":"Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services","volume":"252","author":"Wagner","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib53","unstructured":"Wagner, W., Wagner, P., n.d. Mass Incarceration: The Whole Pie 2024 [WWW Document]. Prison Policy Initiative. URL \u3008https:\/\/www.prisonpolicy.org\/reports\/pie2024.html\u3009 (accessed 8.19.24)."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ADM.0b013e3182584772","article-title":"Methadone dose, take home status, and hospital admission among methadone maintenance patients","volume":"6","author":"Walley","year":"2012","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.5318","article-title":"Incarceration history and access to and receipt of health care in the US","author":"Zhao","year":"2024","journal-title":"JAMA Health Forum Am. Med. Assoc."},{"key":"10.1016\/j.drugalcdep.2025.112775_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drugpo.2019.04.010","article-title":"Fentanyl shock: the changing geography of overdose in the United States","volume":"70","author":"Zoorob","year":"2019","journal-title":"Int. J. Drug Policy"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625002285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:17:43Z","timestamp":1760591863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625002285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"alternative-id":["S0376871625002285"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112775","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112775"}}